CRNX

Crinetics Pharmaceuticals (CRNX) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov^[4], including 5 Phase 3^[1], 5 Phase 2^[2], 2 Phase 1^[3].

Trial NCT05192382^[5] evaluates Paltusotine in Acromegaly with a target enrollment of 111 participants. Trial NCT07144163^[6] evaluates Atumelnant in Congenital Adrenal Hyperplasia with a target enrollment of 150 participants. Trial NCT07159841^[7] evaluates Atumelnant in Congenital Adrenal Hyperplasia with a target enrollment of 153 participants.

CRNX has 5 Form 4 insider filings recorded at the SEC in the past 30 days^[8].